Euro-Med Laboratories Philippines, Inc.
PPSE:EURO1.14
PHP
+0.01
(+0.88%)
ISIN
PHY2352T1098
CUSIP
Y2352T109
Return %
Stock
S&P 500
1Y
18.75
14.20
3Y
37.35
81.12
5Y
-30.06
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Full Time Employees
- 1,200
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Manila Philippines
- IPO Date
- Jul 2, 1998
- Website
- euromedlab.net
- Similar Companies
- Business
- Euro-Med Laboratories Philippines, Inc. is a Philippines-based pharmaceutical and healthcare company primarily engaged in the manufacture, distribution, and marketing of large-volume parenterals, small-volume parenterals, sterile irrigation solutions, hemodialysis concentrates, and specialty pharmaceutical formulations. Incorporated in 1988 and commencing commercial operations in 1991, the company is headquartered in Manila, Philippines, and operates advanced manufacturing facilities utilizing European blow-fill-seal aseptic technology to produce sterile, pyrogen-free medical solutions in plastic containers. The company's core operations are organized into pharmaceutical manufacturing, healthcare services, and food services. Its primary product and service portfolio encompasses large-volume parenterals, including standard intravenous fluids such as dextrose infusions, saline solutions, Ringer's lactate, and therapeutic solutions like mannitol, dextran, and metronidazole infusions; small-volume parenterals, consisting of sterile water for injection, solvent vehicles, and injectable drug diluents packaged in plastic ampoules and vials; specialty and irrigation solutions, comprising hemodialysis concentrates, peritoneal dialysis solutions, and surgical irrigation liquids; secondary pharmaceutical and healthcare products, including ophthalmic drops, respiratory inhalation solutions, topical antiseptics, hospital-grade disinfectants marketed under brands such as Bacticide, and bottled distilled drinking water; and contract manufacturing and analytical laboratory testing services, providing toll formulation, chemical assays, and microbiological quality control testing for domestic and international pharmaceutical firms. Euro-Med Laboratories distributes its pharmaceutical products domestically to private and government hospitals, medical centers, clinics, retail drugstore chains, and healthcare distributors across the Philippines, while maintaining export channels to selected emerging markets in Asia and the Pacific. The company also operates through two principal wholly owned subsidiaries: Hemotek Renal Center, Inc., which manages an extensive network of freestanding and hospital-partnered outpatient hemodialysis centers providing renal replacement therapies, and CafeFrance Corp., which operates quick-service bakery-cafes, institutional food distribution, and catering facilities. In recent developments, Euro-Med Laboratories has advanced several strategic initiatives to expand its production capacity, modernize operational infrastructure, and reinforce its healthcare and commercial service footprint. The company has implemented upgrades across its blow-fill-seal manufacturing lines to increase parenteral output, improve packaging efficiency, and support new product line extensions in renal care solutions and hospital sanitation products. In its healthcare services segment, Euro-Med has continued the geographic expansion of Hemotek Renal Center clinics across provincial regions in the Philippines to address rising nationwide demand for hemodialysis treatments. Concurrently, the company has integrated digital sales force automation systems to enhance pharmaceutical supply chain visibility and hospital inventory replenishment, while maintaining active retail channel growth for CafeFrance and sustaining regular shareholder capital returns through consistent cash dividend distributions.